Protalix BioTherapeutics, Inc. - PLX Net Assets per Single Share

Protalix BioTherapeutics (PLX) is a recognized expert in developing plant-based protein drugs, with a name associated with the safety of therapies for orphan diseases. The business relies on absolute macro-stability and patent protection, as life-saving medicines remain in constant demand. The current figure is 0.90. Stability is ensured by a strong team of R&D specialists. The market trend below clearly demonstrates the price action of this high-tech production.

Professional capital evaluates Protalix BioTherapeutics (PLX) through the lens of intellectual property capitalization, where the proprietary ProCellEx platform creates a fundamental defensive moat. By analyzing the book value per share metric, the investor sees net assets minus all liabilities, which, under strict FDA oversight, allows for an objective measurement of the business's intrinsic value and a determination of the asset's reliability.